Associations among locus coeruleus catecholamines, tau pathology, and memory in aging

Author(s):  
Claire J. Ciampa ◽  
Jourdan H. Parent ◽  
Theresa M. Harrison ◽  
Rebekah M. Fain ◽  
Matthew J. Betts ◽  
...  
2021 ◽  
Vol 80 (4) ◽  
pp. 325-335
Author(s):  
Sarah C Kelly ◽  
Peter T Nelson ◽  
Scott E Counts,

Abstract Locus coeruleus (LC) neurodegeneration is associated with cognitive deterioration during the transition from normal cognition to mild cognitive impairment (MCI) and Alzheimer disease (AD). However, the extent to which LC degenerative processes differentiate cognitively normal, “resilient” subjects bearing a high AD pathological burden from those with MCI or AD remains unclear. We approached this problem by quantifying the number of LC neurons and the percentage of LC neurons bearing AT8 tau pathology, TDP-43 pathology, or a marker for DNA/RNA oxidative damage, in well-characterized subjects diagnosed as normal cognition-low AD pathology (NC-LP), NC-high AD pathology (NC-HP), MCI, or mild/moderate AD. In addition, the severity of pontine arteriolosclerosis in each subject was compared across the groups. There was a trend for a step-wise ∼20% loss of LC neuron number between the NC-LP, NC-HP and MCI subjects despite a successive, significant ∼80%–100% increase in tau pathology between these groups. In contrast, increasing pontine arteriolosclerosis severity scores and LC oxidative stress burden significantly separated the NC-LP/HP and MCI/AD groups via comparative, correlation, and regression analysis. Pontine perfusion, as well as LC neuronal metabolic and redox function, may impact noradrenergic LC modulation of cognition during the preclinical and prodromal stages of AD.


2006 ◽  
Vol 14 (7S_Part_9) ◽  
pp. P509-P510 ◽  
Author(s):  
Heidi IL. Jacobs ◽  
Alex Becker ◽  
Kenneth Kwong ◽  
Federico d'Oleire Uquillas ◽  
Reisa A. Sperling ◽  
...  

2019 ◽  
Vol 15 ◽  
pp. P1113-P1114
Author(s):  
Heidi IL. Jacobs ◽  
Joyita Dutta ◽  
Alex Becker ◽  
Bernard J. Hanseeuw ◽  
Jorge Sepulcre ◽  
...  

2019 ◽  
Vol 15 ◽  
pp. P771-P772
Author(s):  
Dahyun Yi ◽  
Min Soo Byun ◽  
Jun Ho Lee ◽  
So Yeon Jeon ◽  
Gihwan Byeon ◽  
...  

2015 ◽  
Vol 130 (3) ◽  
pp. 349-362 ◽  
Author(s):  
Michiyo Iba ◽  
Jennifer D. McBride ◽  
Jing L. Guo ◽  
Bin Zhang ◽  
John Q. Trojanowski ◽  
...  

2019 ◽  
Author(s):  
Seong Su Kang ◽  
Xia Liu ◽  
Eun Hee Ahn ◽  
Jie Xiang ◽  
Fredric P. Manfredsson ◽  
...  

AbstractAberrant Tau inclusions in the locus coeruleus (LC) are the earliest detectable Alzheimer’s disease (AD)-like neuropathology in the human brain; however, why LC neurons are selectively vulnerable to developing early Tau pathology and degenerating later in disease and whether the LC might seed the stereotypical spread of Tau pathology to the rest of the brain remain unclear. Here we show that 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL), which is produced exclusively in noradrenergic neurons by monoamine oxidase A (MAO-A) metabolism of norepinephrine (NE), activates asparagine endopeptidase (AEP) that cleaves Tau at residue N368 into aggregation- and propagation-prone forms, thereby leading to LC degeneration and the spread of Tau pathology. DOPEGAL triggers AEP-cleaved Tau aggregationin vitroand in intact cells, resulting in LC neurotoxicity and propagation of pathology to the forebrain. Thus, our findings reveal a novel molecular mechanism underlying the selective vulnerability of LC neurons in AD.


2020 ◽  
Author(s):  
Sanne Simone Kaalund ◽  
Luca Passamonti ◽  
Kieren SJ Allinson ◽  
Alexander G Murley ◽  
Trevor W Robbins ◽  
...  

AbstractThe locus coeruleus is the major source of noradrenaline to the brain and contributes to a wide range of physiological and cognitive functions including arousal, attention, autonomic control, and adaptive behaviour. Neurodegeneration and pathological aggregation of tau protein in the locus coeruleus are early features of progressive supranuclear palsy (PSP). This pathology is proposed to contribute to the clinical expression of disease, including the PSP Richardson’s syndrome. We test the hypothesis that tau pathology and neuronal loss are associated with clinical heterogeneity and severity in PSP.We used immunohistochemistry in post mortem tissues from 31 patients with a clinical diagnosis of PSP (22 with Richardson’s syndrome) and 6 control cases. We quantified the presence of hyperphosphorylated tau, the number of pigmented cells indicative of noradrenergic neurons, and the percentage of pigmented neurons with tau-positive inclusions. Ante mortem assessment of clinical severity using the PSP rating scale was available within 1.8 (±0.9) years for 23 patients.We found an average 49% reduction of pigmented neurons in PSP patients relative to controls. The loss of pigmented neurons correlated with disease severity, even after adjusting for disease duration and the interval between clinical assessment and death. The degree of neuronal loss was associated with tau-positive inclusions, with an average of 44% of pigmented neurons displaying tau-inclusions.Degeneration and tau pathology in the locus coeruleus are related to clinical heterogeneity of PSP. The noradrenergic deficit in the locus coeruleus is a candidate target for pharmacological treatment. Recent developments in ultra-high field magnetic resonance imaging to quantify in vivo structural integrity of the locus coeruleus may provide biomarkers for noradrenergic experimental medicines studies in PSP.


2019 ◽  
Vol 15 (7) ◽  
pp. P145-P146
Author(s):  
Dahyun Yi ◽  
Min Soo Byun ◽  
Jun Ho Lee ◽  
So Yeon Jeon ◽  
Gihwan Byeon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document